Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

Phase 1 Completed 95 enrolled Harpoon Therapeutics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin expression.(Phase 2 portion of the study was not conducted.)

Timeline

Start: 2019-04-16
Primary completion: 2023-01-04
Completion: 2023-01-04

Publications

Molloy ME, Austin RJ, Lemon BD, Aaron WH, Ganti V, Jones A, Jones SD, Strobel KL, Patnaik P, Sexton K, Tatalick L, Yu TZ, Baeuerle PA, Law CL, Wesche H. Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors. Clin Cancer Res. 2021 Mar 1;27(5):1452-1462. doi: 10.1158/1078-0432.CCR-20-3392. Epub 2020 Dec 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HPN536	Protein / enzyme biologic	0.006 ug/kg	Intravenous
Subject	HPN536	Protein / enzyme biologic	0.56 ug/kg	Intravenous
Subject	HPN536	Protein / enzyme biologic	0.6 ug/kg	Intravenous
Subject	HPN536	Protein / enzyme biologic	0.9 ug/kg	Intravenous
Subject	HPN536	Protein / enzyme biologic	1.2 ug/kg	Intravenous
Subject	HPN536	Protein / enzyme biologic	1.8 ug/kg	Intravenous
Subject	HPN536	Protein / enzyme biologic	3.6 ug/kg	Intravenous
Subject	HPN536	Protein / enzyme biologic	7.2 ug/kg	Intravenous
Subject	HPN536	Protein / enzyme biologic	14.4 ug/kg	Intravenous

Indications

No indication recorded.